1Francis PT,Nordberg A,Arnold SE.A preclinical view of cholinesterase inhibitors in neuroprotection:do they provide more than symptomatic benefits in Alzheimer's disease?[J].Trends Pharmacol Sci,2005,26 (2):104-111.
2Frolich L,Klinger T,Berger FM.Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease[J].J Neurol Sci,2002,15 (203-204):137-139.
3Borroni B,Agosti C,Martini G,et al.Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients[J].J Neurol Sci,2005,15 (229-230):211-213.
4Pokorna L,Revilla A,Havel J,et al.Capillary zone eletrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives:experimental design and artificial neural network optimization[J].Electrophoresis,1999,20(10):1993-1997.
5Wang R,Tang XC.Neuroprotective effects of huperzine A.A natural cholinesterase inhibitor for the treatment of Alzheimer's disease[J].Neurosignals,2005,14(1-2):71-82.
6Kamal MA,Greig NH,Alhomida AS,et al.Kinetics of Human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent,tolserine[J].Biochem Pharmacol,2000,60(4):561-570.
7Tuppo EE,Arias HR.The role of inflammation in Alzheimer's disease[J].Biochem Cell Biol,2005,37(2):289-305.
8George AJ,Holsinger RM,McLean CA,et al.APP intracellular domain is increased and soluble Aβis reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease[J].Neurobio Dis,2004,16(1):124-132.
9Borroni B,Colciaghi F,Lenzi GL,et al.High cholesterol affects platelet APP processing in controls and in AD patients[J].Neurobiol Aging,2003,24(5):631-636.
10Apelt J,Schliebs R.Beta-amyloid-induced glial expression of both pro-and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology[J].Brain Research,2001,894(1):21-30.
